Results 141 to 150 of about 2,116 (170)

Clinical and economic evaluation of tralokinumab for atopic dermatitis

Journal of Managed Care & Specialty Pharmacy
Tralokinumab is the first selective interleukin 13 inhibitor approved for moderate to severe atopic dermatitis. This article reports the findings of a comprehensive literature review and extensive economic analysis to assess tralokinumab's safety, effectiveness, and cost.
Ryan A, Moreau, Angela Y, Su, Molly M, Csere, Ryan M, Shan, Christina M, Polomoff   +4 more
openaire   +2 more sources

Tralokinumab in elderly atopic dermatitis

Italian Journal of Dermatology and Venereology, 2023
Napolitano, Maddalena, Potestio, Luca, Menna, Luca, Megna, Matteo, Fabbrocini, Gabriella, Patruno, Cataldo   +5 more
openaire   +3 more sources

Tralokinumab

Reactions Weekly
  +5 more sources

Review of Tralokinumab in the Treatment of Atopic Dermatitis

Annals of Pharmacotherapy, 2023
Steven Feldman, Lindsay Strowd, Rohan Singh   +2 more
exaly  

Safety of tralokinumab in atopic dermatitis

British Journal of Dermatology, 2023
openaire   +2 more sources

Tralokinumab

Drugs of the Future, 2014
openaire   +1 more source

Dupilumab/tralokinumab

Reactions Weekly
  +4 more sources

Tralokinumab for atopic dermatitis: a promising new therapy

British Journal of Dermatology, 2020
D.E. Morra, A.M. Drucker
openaire   +2 more sources

Ciclosporin/tralokinumab

Reactions Weekly
openaire   +2 more sources

Population Pharmacokinetics of Tralokinumab in Adult Subjects With Moderate to Severe Atopic Dermatitis

Clinical Pharmacology in Drug Development, 2022
exaly